SERUM LEVELS OF SOLUBLE INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1, CD54) IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER - CORRELATION WITH HISTOLOGICAL EXPRESSION OF ICAM-1 AND TUMOR STAGE
A. Grothey et al., SERUM LEVELS OF SOLUBLE INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1, CD54) IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER - CORRELATION WITH HISTOLOGICAL EXPRESSION OF ICAM-1 AND TUMOR STAGE, British Journal of Cancer, 77(5), 1998, pp. 801-807
The expression of the intercellular adhesion molecule-1 (ICAM-1, CD54)
seems to have an influence on the metastatic behaviour of tumour cell
s via immunological mechanisms. Recently, a soluble form of ICAM-1 was
identified in physiological fluids. We analysed the serum levels of s
ICAM-1 in patients with non-small-cell lung cancer (NSCLC) and healthy
individuals using a sandwich ELISA technique. Sera from 51 patients w
ith NSCLC were tested for slCAM-1 (46 male, five female; age 38-81 yea
rs, median 64 years), 29 of whom presented with localized and 26 with
metastatic disease. The control group consisted of 40 healthy individu
als (20 smokers, 20 non-smokers). Immunohistochemical analysis of ICAM
-1 in tumour cells was performed in 20 cases. Patients with NSCLC had
significantly higher serum levels of sICAM-1 compared with healthy non
-smokers (P = 0.00001) and smokers (P = 0.0328). Metastatic disease wa
s associated with higher sICAM-1 than localized tumours (P = 0.0013).
Only 11 out of 23 patients with localized NSCLC had sICAM-1 levels >30
0 ng ml(-1), compared with 25 out of 28 patients with metastatic disea
se. Histological expression of ICAM-1 was positively correlated with s
erum slCAM-1 (P = 0.0399). No difference was observed between histolog
ical tumour types with regard to slCAM-1 or NSCLC expression of ICAM-1
. In sequential analysis (13 patients), rising sICAM-1 levels predicte
d a short-term fatal outcome (P = 0.0054) but, overall, slCAM-1 levels
did not correlate with prognosis. In the control group, smokers showe
d significantly higher levels than non-smokers (P = 0.0016). In contra
st to patients with NSCLC, sICAM-1 in the control group was correlated
to the leucocyte count (r = 0.580, P = 0.003). in conclusion, serum l
evels of sICAM-1 seem to be associated with tumour burden anti histolo
gical expression of ICAM-1 in patients with NSCLC. However, the (patho
-) physiological role of ICAM-1 in NSCLC remains to be determined.